Prediction of Relapse after Allogeneic Stem Cell Transplantation Using Individualized Minimal Residual Markers:The Prospective Nordic Study NMDSG14B

Autor: Daniel Olsson, Sten Eirik W. Jacobsen, Kirsten Groenbaek, Soili Kytölä, Duruta Weber, Magnus Tobiasson, Jörg Cammenga, Lone Smidstrup Friis, Tatjana Pandzic, Lennart Nilsson, Ingunn Dybedal, Johanna Illman, Simone Weström, Lucia Cavelier, Eva Hellstrom Lindberg, Olle Werlenius, Fryderyk Lorentz, Astrid Olsnes Kittang, Freja Ebeling, Stephan Mielke, Bengt Rasmussen, Gitte Olesen, Elisabeth Ejerblad, Gunilla Walldin, Andreas T. Björklund, Marios Dimitriou

Publikováno v: Tobiasson, M, Pandzic, T, Illmann, J, Nilsson, L, Weström, S, Olsson, D, Ejerblad, E, Olsnes Kittang, A, Olesen, G, Werlenius, O, Björklund, A T, Lorentz, F, Rasmussen, B E H, Cammenga, J, Dimitriou, M D, Kytölä, S, Walldin, G, Groenbaek, K, Mielke, S, Waelgaard Jacobsen, S E, beling, F, Cavelier, L, Friis, L S, Dybedal, I, Hellström-Lindberg, E & Weber, D 2020, ' Prediction of Relapse after Allogeneic Stem Cell Transplantation Using Individualized Minimal Residual Markers : The Prospective Nordic Study NMDSG14B ', Blood, vol. 136, no. Suppl. 1, pp. 5-6 . https://doi.org/10.1182/blood-2020-138782

Introduction One third of patients with myelodysplastic syndrome (MDS) will relapse after allogeneic stem cell transplantation (SCT), with a dismal prognosis. Early detection of relapse enables pre-emptive treatment and may potentially reduce relapse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cf759f79d27be0d17a7972a7caeeaac
https://portal.findresearcher.sdu.dk/da/publications/1987205d-9146-40f1-b5e1-94cb7b1cd006